In July 2005, the anti-AIDS drug sifuvirtide, independently developed by China and patented in China and the United States, entered Phase I labor trials. Sifuvirtide is a fourth-generation anti-AIDS drug independently developed by China. It is also the first anti-AIDS biotech drug in my country to obtain a U.S. patent authorization. Its international patents have entered Europe, Japan, Russia and other countries and regions. Industrial influence: If this new drug is approved for marketing once it completes trials, it will be a major breakthrough for China in the field of biotechnology.